PA
ORIC icon

Parallel Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Parallel Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$899 Hold
83
– – ﹤0.01% 3705
2026
Q1 		$1.05K Hold
83
– – ﹤0.01% 3535
2025
Q4 		$679 Hold
83
– – ﹤0.01% 3364
2025
Q3 		$996 Hold
83
– – ﹤0.01% 3220
2025
Q2 		$842 Buy
+83
New +$557 ﹤0.01% 3228
2022
Q1 		– Sell
-628
Closed -$9K – 3183
2021
Q4 		$9K Buy
628
+626
+31,300% +$9.76K ﹤0.01% 2164
2021
Q3 		$0 Buy
+2
New +$41 ﹤0.01% 3212

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors's ORIC Position: Q2 2026 in Review

Parallel Advisors held its Oric Pharmaceuticals (ORIC) position steady in Q2 2026 at 83 shares worth $899. The position accounts for ﹤0.01% of the portfolio, ranked #3705.

Parallel Advisors first reported a position in ORIC in Q3 2021 and has held it in 7 quarters since. The position peaked at $9K in Q4 2021. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Parallel Advisors held 83 shares of Oric Pharmaceuticals worth $899 as of Q2 2026.
  • Parallel Advisors left its Oric Pharmaceuticals share count unchanged in Q2 2026.
  • Oric Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3705 holding.
  • Parallel Advisors first reported a position in Oric Pharmaceuticals in Q3 2021 and has held it in 7 quarters since.
  • Parallel Advisors's Oric Pharmaceuticals position peaked at $9K in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.